Johnson & Johnson and AstraZeneca are studying whether modifying their COVID-19 vaccines can reduce or eliminate the risk of rare blood clots
- Johnson & Johnson and AstraZeneca-University of Oxford have begun studying whether their COVID-19 vaccines can be modified
- Both shots have been linked to a risk of blood clots along with a low platelet-count condition known as thrombocytopenia
- Scientists hope to identify the causes behind the blood clots and maybe re-engineer the shots by next year
- In the U.S., J&J’s vaccine has been linked to 0.3 cases of rare blood clots per 100,000 doses and AstraZeneca’s jab linked to 1-2 cases per 100,000
- It comes one day after it was revealed the FDA is adding a new warning to the label of J&J’s vaccine due the risk of a rare autoimmune disorder.
Click through to read the rest of the article.